Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*
Antihypertensive Drugs Market by Therapeutic Class (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others Distribution Channel): Global Opportunity Analysis and Industry Forecast, 2019–2026 Update Available On-Demand
| A00337 | Pages: 222 | Dec 2019 | 11094 Views | | |
| Author(s) : Sagar Mukhekar , Onkar Sumant | Tables: 84 | Charts: 63 | Formats*: | |
COVID-19
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Antihypertensive Drugs Market
Request Now !The global antihypertensive drugs market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.
Hypertension is defined as a long-term medical condition that is marked by high pressure of blood in the arteries, which is persistently elevated. Antihypertensive are used for treatment of patients suffering from high blood pressure-also known as hypertension. Hypertension is a major disorder accompanied with serious complications such as heart attack, heart failure, and dementia. Therefore, hypertension requires early diagnosis and treatment. Some of the drugs used for the treatment of hypertension include diuretics, ACE inhibitors, and vasodilators.
The factor that contribute toward antihypertensive drugs market growth of the global antihypertensive drugs market include surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension is a major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle boost the growth of the market. However, recent patent expirations are anticipated to hinder the growth of the antihypertensive market. Conversely, rise in research related to antihypertensive drugs is expected to offer lucrative opportunities during the forecast period.
Global Antihypertensive Drugs Market Segmentation
The global antihypertensive drugs market size is studied on the basis of therapeutic class, distribution channel, and region to provide a detailed assessment of the market. Depending on therapeutic class, the market is divided into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. By distribution channel, it is categorized into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, the antihypertensive drugs market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
Get more information on this report : Request Sample Pages
Segment Review
According to therapeutic class, calcium channel blockers occupied the largest antihypertensive drugs market share in 2018, owing to lesser side effects exhibited by these drugs as compared to the other type of antihypertensive drugs. However, the ACE inhibitors segment is anticipated to depict fastest growth during the forecast period, due to benefits offered such as positive impact on overall health and decrease in progression of kidney diseases.
Antihypertensive Drugs Market
By Drug Class
Calcium Channel Blockers segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.
Get more information on this report : Request Sample Pages
By distribution channel, the hospitals segment occupied the largest share. This is attributable to rise in number of hospitals worldwide. Furthermore, antihypertensive drugs are prescription-based medications, which are mostly prescribed by the specialized healthcare professionals available in hospitals, thereby augmenting the growth of this segment. On the contrary, the e-commerce segment is expected to exhibit the highest growth rate during the forecast period, owing to surge in the use of internet across the globe.
Antihypertensive Drugs Market
By Distribution Channel
E-commerce Websites and Online Drug Stores is projected as one of the most lucrative segment.
Get more information on this report : Request Sample Pages
Region wise, North America garnered the major share of the antihypertensive drugs market in 2018, and is expected to continue this trend in the near future, attributable to easy availability of antihypertensive drugs. Moreover, surge in incidence of hypertension and rise in geriatric population significantly contribute toward the growth of the market in this region. However, Asia-Pacific is projected to register the highest growth during the forecast period, owing to surge in awareness related to the use of antihypertensive drugs. Furthermore, the constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and Malaysia.
Antihypertensive Drugs Market
By Region
Asia-Pacific region would exhibit the highest CAGR of 4.2% during 2019-2026.
Get more information on this report : Request Sample Pages
The global antihypertensive drugs market is highly competitive, and prominent players have adopted various strategies for garnering maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.
Key Benefits for Stakeholders
- This report entails a detailed quantitative analysis along with the current global antihypertensive drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The antihypertensive drugs market forecast is studied from 2019 to 2026.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Therapeutic Class
- Diuretics
- ACE Inhibitors
- Calcium Channel Blockers
- Beta-adrenergic Blockers
- Vasodilators
- Others
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- E-commerce
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.2.1. List of key players profiled in the report
1.3. Research methodology
1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Key forces shaping antihypertensive industry/market
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Surge in geriatric population worldwide
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in prevalence of hypertension across the globe
3.4.2. Restraint
3.4.2.1. Patent expirations of blockbuster drugs
3.4.3. Opportunity
3.4.3.1. High growth potential in developing economies
3.4.4. Impact Analyses
CHAPTER 4: ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Diuretics
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country
4.3. ACE Inhibitors
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country
4.4. Calcium Channel Blockers
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country
4.5. Beta-Adrenergic Blockers
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country
4.6. Vasodilators
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis by country
4.7. Others
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis by country
CHAPTER 5: ANTIHYPERTENSIVE DRUGS MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Retail Pharmacy
5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country
5.3. Hospital Pharmacy
5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country
5.4. E-commerce Websites & Online Drug Stores
5.4.1. Market size and forecast, by region
5.4.2. Market analysis by country
CHAPTER 6: ANTIHYPERTENSIVE DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by drug class
6.2.2.1.2. U.S. market size and forecast, by distribution channel
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by drug class
6.2.2.2.2. Canada market size and forecast, by distribution channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by drug class
6.2.2.3.2. Mexico market size and forecast, by distribution channel
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by distribution channel
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by drug class
6.3.2.1.2. Germany market size and forecast, by distribution channel
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by drug class
6.3.2.2.2. France market size and forecast, by distribution channel
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by drug class
6.3.2.3.2. UK market size and forecast, by distribution channel
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by drug class
6.3.2.4.2. Italy market size and forecast, by distribution channel
6.3.2.5. Rest of Europe
6.3.2.5.1. Rest of Europe market size and forecast, by drug class
6.3.2.5.2. Rest of Europe market size and forecast, by distribution channel
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by distribution channel
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by drug class
6.4.2.1.2. Japan market size and forecast, by distribution channel
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by drug class
6.4.2.2.2. China market size and forecast, by distribution channel
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by drug class
6.4.2.3.2. India market size and forecast, by distribution channel
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by drug class
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by distribution channel
6.4.3. Asia-Pacific market size and forecast, by drug class
6.4.4. Asia-Pacific market size and forecast, by distribution channel
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by drug class
6.5.2.1.2. Brazil market size and forecast, by distribution channel
6.5.2.2. South Africa
6.5.2.2.1. South Africa market size and forecast, by drug class
6.5.2.2.2. South Africa market size and forecast, by distribution channel
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia market size and forecast, by drug class
6.5.2.3.2. Saudi Arabia market size and forecast, by distribution channel
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by drug class
6.5.2.4.2. Rest of LAMEA market size and forecast, by distribution channel
6.5.3. LAMEA market size and forecast, by drug class
6.5.4. LAMEA market size and forecast, by distribution channel
CHAPTER 7: COMPANY PROFILES
7.1. AstraZeneca plc
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. Boehringer Ingelheim International GmbH
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. Daiichi Sankyo Company, Limited
7.3.1. Company overview
7.3.2. Operating business segments
7.3.3. Product portfolio
7.3.4. Business performance
7.3.5. Key strategic moves and developments
7.4. Johnson & Johnson
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Lupin
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Novartis AG.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. Merck & Co., Inc
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Pfizer Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. SANOFI
7.10.1. Company overview
7.10.2. Operating business segments
7.10.3. Product portfolio
7.10.4. Business performance
LIST OF TABLES
TABLE 01. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, 2018-2026 ($MILLION)
TABLE 02. DIURETICS ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. ACE INHIBITORS ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. CALCIUM CHANNEL BLOCKERS ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BETA-ADRENERGIC BLOCKERS ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. VASODILATORS ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. OTHERS ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2018-2026 ($MILLION )
TABLE 09. ANTIHYPERTENSIVE DRUGS MARKET REVENUE FOR RETAIL PHARMACY, BY REGION 2018–2026($MILLION)
TABLE 10. ANTIHYPERTENSIVE DRUGS MARKET REVENUE FOR HOSPITAL PHARMACY, BY REGION 2018–2026 ($MILLION)
TABLE 11. ANTIHYPERTENSIVE DRUGS MARKET REVENUE FOR E-COMMERCE WEBSITES & ONLINE DRUG STORES, BY REGION 2018–2026 ($MILLION)
TABLE 12. ANTIHYPERTENSIVE DRUGS MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE 13. NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 14. U.S. ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 15. U.S. ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 16. CANADA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 17. CANADA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 18. MEXICO ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 19. MEXICO ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 20. NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 21. NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 22. EUROPE ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 23. GERMANY ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 24. GERMANY ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 25. FRANCE ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 26. FRANCE ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 27. UK ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 28. UK ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 29. ITALY ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 30. ITALY ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 31. REST OF EUROPE ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 32. REST OF EUROPE ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 33. EUROPE ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 34. EUROPE ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 35. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 36. JAPAN ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 37. JAPAN ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 38. CHINA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 39. CHINA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 40. INDIA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 41. INDIA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 42. REST OF ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 43. REST OF ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 44. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 45. ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 46. LAMEA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 47. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 48. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 49. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 50. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 51. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 52. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 53. REST OF LAMEA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 54. REST OF LAMEA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026 ($MILLION)
TABLE 55. LAMEA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 56. LAMEA ANTIHYPERTENSIVE DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2019–2026($MILLION)
TABLE 57. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 58. ASTRAZENECA: OPERATING BUSINESS SEGMENTS
TABLE 59. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 60. BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 61. BOEHRINGER INGELHEIM: PRODUCT BUSINESS SEGMENTS
TABLE 62. BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 63. DAIICHI-SANKYO.: COMPANY SNAPSHOT
TABLE 64. DAIICHI-SANKYO.: OPERATING BUSINESS SEGMENTS
TABLE 65. DAIICHI-SANKYO.: PRODUCT PORTFOLIO
TABLE 66. J&J: COMPANY SNAPSHOT
TABLE 67. J&J: OPERATING BUSINESS SEGMENTS
TABLE 68. J&J: PRODUCT PORTFOLIO
TABLE 69. LUPIN: COMPANY SNAPSHOT
TABLE 70. LUPIN: OPERATING SEGMENTS
TABLE 71. LUPIN: PRODUCT PORTFOLIO
TABLE 72. NOVARTIS: COMPANY SNAPSHOT
TABLE 73. NOVARTIS: OPERATING BUSINESS SEGMENTS
TABLE 74. NOVARTIS: PRODUCT PORTFOLIO
TABLE 75. MERCK: COMPANY SNAPSHOT
TABLE 76. MERCK: OPERATING SEGMENTS
TABLE 77. MERCK: PRODUCT PORTFOLIO
TABLE 78. PFIZER: COMPANY SNAPSHOT
TABLE 79. PFIZER: OPERATING SEGMENTS
TABLE 80. PFIZER: PRODUCT PORTFOLIO
TABLE 81. SUN PHARMA: COMPANY SNAPSHOT
TABLE 82. SUN PHARMA: PRODUCT PORTFOLIO
TABLE 83. SANOFI: COMPANY SNAPSHOT
TABLE 84. SANOFI: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 10. IMPACT ANALYSES, ANTIHYPERTENSIVE DRUGS MARKET
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DIURETICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ACE INHIBITORS ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CALCIUM CHANNEL BLOCKERS ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BETA-ADRENERGIC BLOCKERS ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF VASODILATORS ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF OTHERS ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ANTIHYPERTENSIVE DRUGS MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ANTIHYPERTENSIVE DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2018 & 2026 (%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF ANTIHYPERTENSIVE DRUGS MARKET FOR E-COMMERCE WEBSITES & ONLINE DRUG STORES, BY COUNTRY, 2018 & 2026 (%)
FIGURE 20. U.S. ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 21. CANADA ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 22. MEXICO ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 23. COMPARISON OF MALE GERIATRIC POPULATION IN EUROPEAN COUNTRIES, 2017 (MILLION)
FIGURE 24. GERMANY ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 25. FRANCE ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 26. UK ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 27. ITALY ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 28. REST OF EUROPE ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 29. JAPAN ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 30. CHINA ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 31. INDIA ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 32. REST OF ASIA-PACIFIC ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 33. BRAZIL ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 34. SOUTH AFRICA ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 35. SAUDI ARABIA ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 36. REST OF LAMEA ANTIHYPERTENSIVE DRUGS MARKET, 2018-2026 ($MILLION)
FIGURE 37. ASTRAZENECA: NET SALES, 2016–2018 ($MILLION)
FIGURE 38. ASTRAZENECA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 39. BOEHRINGER INGELHEIM: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. BOEHRINGER INGELHEIM: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41. BOEHRINGER INGELHEIM: REVENUE SHARE BY REGION, 2018(%)
FIGURE 42. DAIICHI-SANKYO: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. DAIICHI-SANKYO: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44. DAIICHI-SANKYO: REVENUE SHARE BY REGION, 2018(%)
FIGURE 45. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 46. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 47. J&J: REVENUE SHARE BY REGION, 2018(%)
FIGURE 48. LUPIN: NET SALES, 2017–2019 ($MILLION)
FIGURE 49. LUPIN: REVENUE SHARE BY REGION, 2019(%)
FIGURE 50. NOVARTIS AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 51. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 52. NOVARTIS AG: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 53. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 54. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 55. MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 56. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 57. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 58. PFIZER: REVENUE SHARE BY REGION, 2018(%)
FIGURE 59. SUN PHARMA: NET SALES, 2016–2018 ($MILLION)
FIGURE 60. SUN PHARMA: REVENUE SHARE BY REGION, 2018(%)
FIGURE 61. SANOFI: NET SALES, 2016–2018 ($MILLION)
FIGURE 62. SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 63. SANOFI: REVENUE SHARE BY REGION, 2018(%)
Antihypertensive drugs are used to treat high blood pressure. High blood pressure is a chronic condition, which is related to rise in pressure of blood in the arteries of the patient. Furthermore, the condition is accompanied with other severe and fatal conditions such as heart attack and dementia. This medical condition is treated by using drugs such as beta blockers, vasodilators, and calcium channel blockers.
The utilization of antihypertensives has witnessed a significant growth, owing to surge in incidence of hypertension worldwide. Furthermore, other factors such as rise in geriatric population, surge in awareness related to complication of hypertension, and sedentary lifestyle are the factors that fuel the growth of the market. However, expiration of patents is a major factor that hinders the growth of the market.
Q1. What is the total market value of antihypertensive drugs market report ?
A. The total market value of antihypertensive drugs market is $22,556.50 million in 2018.
Q2. What would be forecast period in the market report?
A. The forcast period for antihypertensive drugs market is 2019 to 2026
Q3. What is the market value of antihypertensive drugs market in 2019?
A. The market value of antihypertensive drugs market in 2019 is $23,256.30 million
Q4. Which is base year calculated in the antihypertensive drugs market report?
A. The base year is 2018 in antihypertensive drugs market
Q5. Which are the top companies hold the market share in antihypertensive drugs market?
A. Top companies such as, Boehringer Ingelheim International GmbH, Johnson & Johnson, Novartis AG., Merck & Co., Inc, and Daiichi Sankyo Company, Limited., held a high market position in 2018.
Q6. Which is the most influencing segment growing in the antihypertensive drugs market report?
A. Calcium channel blockers segment is the most influencing segment growing in the antihypertensive drugss market
Q7. What are the key trends in the antihypertensive drugs market report?
A. The key trend in the antihypertensive drugs market is the rise in prevalence of hypertension across the globe which drives the growth of the market.
Q8. What are the market values / growth % of emerging countries?
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 5.1%.
Download Sample
Purchase Full Report of
Antihypertensive Drugs Market
- Online Only
- $3,456
- Online cloud access only
- Restricted print, copy, paste & download
- Read only
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
- $3,840
- Restricted to one authorized user
- One print only
- Available in
Excel - Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
- $5,769
- Restricted to one authorized user
- One print only
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
- $6,450
- Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF - $8,995
- Unlimited
within
company/enterprise - Available in Excel & PDF
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Library Membership
- $ 699/mo
- Published Content
E-access - Company Profiles
E-access - Newly Added Content Access
- 10 PDF
Downloads - 5 Excel Data
Pack Downloads - 250 Company Profiles PDF Downloads
-
Start reading instantly.
Buy Now
This title and over 12,000+ are available on the Avenue Library. T&C*.
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers